Compare Dr. Reddys with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs LUPIN - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB LUPIN DR. REDDYS LAB/
LUPIN
 
P/E (TTM) x 22.2 47.9 46.4% View Chart
P/BV x 3.3 2.5 135.3% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DR. REDDYS LAB   LUPIN
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
LUPIN
Mar-19
DR. REDDYS LAB/
LUPIN
5-Yr Chart
Click to enlarge
High Rs2,875986 291.6%   
Low Rs1,888720 262.1%   
Sales per share (Unadj.) Rs930.2369.5 251.8%  
Earnings per share (Unadj.) Rs117.413.4 876.0%  
Cash flow per share (Unadj.) Rs185.837.4 496.9%  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs844.4303.7 278.0%  
Shares outstanding (eoy) m166.07452.49 36.7%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.62.3 110.9%   
Avg P/E ratio x20.363.6 31.9%  
P/CF ratio (eoy) x12.822.8 56.2%  
Price / Book Value ratio x2.82.8 100.4%  
Dividend payout %17.00-   
Avg Mkt Cap Rs m395,496386,064 102.4%   
No. of employees `00022.017.7 124.2%   
Total wages/salary Rs m33,56231,513 106.5%   
Avg. sales/employee Rs Th7,032.89,453.8 74.4%   
Avg. wages/employee Rs Th1,527.91,782.0 85.7%   
Avg. net profit/employee Rs Th887.7343.0 258.8%   
INCOME DATA
Net Sales Rs m154,482167,182 92.4%  
Other income Rs m3,3753,640 92.7%   
Total revenues Rs m157,857170,822 92.4%   
Gross profit Rs m31,78228,822 110.3%  
Depreciation Rs m11,34810,850 104.6%   
Interest Rs m8893,078 28.9%   
Profit before tax Rs m22,92018,534 123.7%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m43838 1,168.0%   
Extraordinary Inc (Exp) Rs m0-3,400 0.0%   
Tax Rs m3,8589,017 42.8%   
Profit after tax Rs m19,5006,066 321.5%  
Gross profit margin %20.617.2 119.3%  
Effective tax rate %16.848.7 34.6%   
Net profit margin %12.63.6 347.9%  
BALANCE SHEET DATA
Current assets Rs m111,101138,536 80.2%   
Current liabilities Rs m58,97361,299 96.2%   
Net working cap to sales %33.746.2 73.0%  
Current ratio x1.92.3 83.4%  
Inventory Days Days7984 94.7%  
Debtors Days Days94112 83.8%  
Net fixed assets Rs m101,245127,516 79.4%   
Share capital Rs m830905 91.7%   
"Free" reserves Rs m139,406136,517 102.1%   
Net worth Rs m140,236137,422 102.0%   
Long term debt Rs m22,00066,417 33.1%   
Total assets Rs m224,656279,494 80.4%  
Interest coverage x26.87.0 381.5%   
Debt to equity ratio x0.20.5 32.5%  
Sales to assets ratio x0.70.6 115.0%   
Return on assets %9.13.3 277.4%  
Return on equity %13.94.4 315.0%  
Return on capital %14.98.9 167.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m88,67359,414 149.2%   
Fx outflow Rs m19,10422,282 85.7%   
Net fx Rs m69,56937,132 187.4%   
CASH FLOW
From Operations Rs m28,70416,660 172.3%  
From Investments Rs m-7,727-32,825 23.5%  
From Financial Activity Rs m-21,3267,441 -286.6%  
Net Cashflow Rs m-314-8,724 3.6%  

Share Holding

Indian Promoters % 25.5 46.6 54.7%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 5.4 11.3 47.8%  
FIIs % 35.3 31.9 110.7%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 10.1 151.5%  
Shareholders   75,885 98,259 77.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  ELDER PHARMA  NOVARTIS  PANACEA BIOTECH  

Compare DR. REDDYS LAB With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 334 Points Lower; IT and Telecom Stocks Witness Huge Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day deep in the red. At the closing bell, the BSE Sensex stood lower by 334 points (down 0.9%).

Related Views on News

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Oct 22, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS